Kalliopi Pafili1, Theano Penlioglou1, Dimitri P Mikhailidis2, Nikolaos Papanas1. 1. Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece. 2. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London (UCL), London, UK.
Abstract
PURPOSE OF REVIEW: To critically review the literature describing links between mean platelet volume (MPV) and cardiovascular disease (CVD). We will focus on coronary artery disease (CAD). The MPV is measured routinely as part of a routine blood count. RECENT FINDINGS: There is accumulating evidence showing that the MPV may predict CVD, as well as outcomes in patients with CAD. There is also evidence linking MPV and comorbidities (e.g. diabetes mellitus and impaired glycaemic control) that are expected in patients with CAD. The effect on MPV of drugs commonly used to treat CAD has not been clarified, but there is some evidence that they may exert a beneficial effect on the MPV. More specifically, the MPV may predict the effect of antiplatelet drugs (e.g. clopidogrel). There is also evidence relating MPV to stroke, atrial fibrillation, coronary artery ectasia and periprocedural outcomes after percutaneous coronary intervention (PCI). SUMMARY: Measuring the MPV may prove useful in CVD risk assessment in patients with established CAD or at risk of developing CAD. Overall, there is evidence pointing to the role of MPV as a contributor rather than simple marker of CVD.
PURPOSE OF REVIEW: To critically review the literature describing links between mean platelet volume (MPV) and cardiovascular disease (CVD). We will focus on coronary artery disease (CAD). The MPV is measured routinely as part of a routine blood count. RECENT FINDINGS: There is accumulating evidence showing that the MPV may predict CVD, as well as outcomes in patients with CAD. There is also evidence linking MPV and comorbidities (e.g. diabetes mellitus and impaired glycaemic control) that are expected in patients with CAD. The effect on MPV of drugs commonly used to treat CAD has not been clarified, but there is some evidence that they may exert a beneficial effect on the MPV. More specifically, the MPV may predict the effect of antiplatelet drugs (e.g. clopidogrel). There is also evidence relating MPV to stroke, atrial fibrillation, coronary artery ectasia and periprocedural outcomes after percutaneous coronary intervention (PCI). SUMMARY: Measuring the MPV may prove useful in CVD risk assessment in patients with established CAD or at risk of developing CAD. Overall, there is evidence pointing to the role of MPV as a contributor rather than simple marker of CVD.
Authors: Amarise Little; Yao Hu; Quan Sun; Deepti Jain; Jai Broome; Ming-Huei Chen; Florian Thibord; Caitlin McHugh; Praveen Surendran; Thomas W Blackwell; Jennifer A Brody; Arunoday Bhan; Nathalie Chami; Paul S de Vries; Lynette Ekunwe; Nancy Heard-Costa; Brian D Hobbs; Ani Manichaikul; Jee-Young Moon; Michael H Preuss; Kathleen Ryan; Zhe Wang; Marsha Wheeler; Lisa R Yanek; Goncalo R Abecasis; Laura Almasy; Terri H Beaty; Lewis C Becker; John Blangero; Eric Boerwinkle; Adam S Butterworth; Hélène Choquet; Adolfo Correa; Joanne E Curran; Nauder Faraday; Myriam Fornage; David C Glahn; Lifang Hou; Eric Jorgenson; Charles Kooperberg; Joshua P Lewis; Donald M Lloyd-Jones; Ruth J F Loos; Yuan-I Min; Braxton D Mitchell; Alanna C Morrison; Deborah A Nickerson; Kari E North; Jeffrey R O'Connell; Nathan Pankratz; Bruce M Psaty; Ramachandran S Vasan; Stephen S Rich; Jerome I Rotter; Albert V Smith; Nicholas L Smith; Hua Tang; Russell P Tracy; Matthew P Conomos; Cecelia A Laurie; Rasika A Mathias; Yun Li; Paul L Auer; Timothy Thornton; Alexander P Reiner; Andrew D Johnson; Laura M Raffield Journal: Hum Mol Genet Date: 2022-02-03 Impact factor: 5.121
Authors: Eleonora Palella; Rossella Cimino; Salvatore A Pullano; Antonino S Fiorillo; Elio Gulletta; Antonio Brunetti; Daniela P Foti; Marta Greco Journal: Int J Environ Res Public Health Date: 2020-01-01 Impact factor: 3.390